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Background: APOE testing is increasingly important to identify
candidates eligible for Alzheimer’s trials. How best to provide ge-
netic services for the disclosure of APOE results remains unclear.
Both telephone and real-time videoconferencing (RTVC) have
been shown to be feasible for remote delivery of genetic services,
but outcomes have not been compared in a randomized trial.
Methods: The Alzheimer’s Prevention Initiative Generation Study
1 (NCT02565511) is enrolling cognitively normal APOE e4 homo-
zygotes aged 60-75 years and includes a standardized approach to
APOE disclosure. Some study sites do not have genetic providers to
provide counseling and test disclosure to participants. CONNECT
4 APOE (NCT02978729) is a multi-site randomized study to eval-
uate the relative advantages of RTVC disclosure over telephone for
disclosure of APOE genotype results in a large clinical trial. Partic-
ipants are randomized to disclosure of results by phone or RTVC;
counselors use standardized counseling checklists, risk estimates
and visual aids. Knowledge and psychosocial outcomes are
measured at various time points. Results: In a planned interim anal-
ysis, 410 participants have been randomized (201 to RTVC, 209 to
phone disclosure). Mean participant age is 67 years, 64% are fe-
male, 93% white, and >99% have a family history of dementia.
124 (31%) are APOE e4 homozygotes and 157 (39%) are heterozy-
gotes. Participant characteristics and APOE results did not differ
significantly between arms. In this early planned analysis, therewere no statistically significant differences in change in any
measured outcome from baseline to 2-7 days or 6 weeks post-
disclosure (Table 1). Those in the telephone arm reported less in-
crease in disease specific-distress, although this was not statistically
significant. Satisfaction with services was slightly higher in the
telephone disclosure arm post-disclosure (0.8 higher in telephone
arm, p¼0.07). Further analysis by APOE result (heterozygote v. ho-
mozygote v. noncarrier) will be completed to better understand if
outcomes are similar by test result. Conclusions: Data from this
ongoing investigation will help inform the optimal delivery method
of genetic disclosure, and has potential implications for the imple-
mentation of APOE testing to screen individuals and families at risk
for Alzheimer’s disease dementia in the clinic.P4-655 ADDRESSING AD HEALTH DISPARITIESTHROUGH A CULTURAL LENSToni C. Antonucci1, Kristine J. Ajrouch1,2, Laura B. Zahodne1,
Irving Vega1, Noah J. Webster1, 1University of Michigan, Ann
Arbor, MI, USA; 2Eastern Michigan University, Ypsilanti, MI,
USA. Contact e-mail: tca@umich.eduBackground: Health disparities affect the diagnosis, treatment and
care of Alzheimer’s Disease (AD). While some information is
available in each of these areas, much less is known about the
role of cultural contexts. The Michigan Center for Contextual Fac-
tors in Alzheimer’s Disease (MCCFAD) explores these issues
through community health events embedded in the Arab American
and Latinx communities. Methods: Preliminary data are offered
from 8 community events, four each held at culturally suitable lo-
cations in the Dearborn and Grand Rapids areas of Michigan,
providing a trustworthy atmosphere. Events were widely advertised
in the community using ethnic mediums (e.g., Arabic-language ra-
dio, social media, community partners and community advisory
board members). During the events presentations were made by
AD experts with input and feedback sought fromCommunity Advi-
sory Board members. Results: Presentations were given in English
with Arabic or Spanish speakers integrally involved; and ethnically
appropriate food was provided at each event. On average 30 to 60
people attended each event, with over 300 attendees in all. Topics
covered included: What is AD; Top AD stories in the news; How
to reduce risk of AD; the Healthy brain. Most attendees were young
or middle aged, i.e. 20-50. Over 70% of the attendees indicated they
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about AD. Overwhelmingly, people were quite positive in their
evaluations of the events (above 4.5 on 5-point scale). Cultural is-
sues were always raised: Do ‘we’ get it more than others; Does it
run in ‘our’ families;What should family members do? Participants
specifically mentioned problems dealing with the cultural stigma
around AD. In both Arab American and Latinx communities, great
pride was expressed in the cultural norm of ‘taking care of our el-
ders’. At the same time, people consistently mentioned the shame
associated with the disease, resulting in denial and the inability to
reach out for assistance, even when desperately needed. Conclu-
sions: Culturally targeted and sensitive community health events
can identify health disparity issues within a cultural context.P4-656 CROSS-LAGGED MODELLING OFGLOBAL COGNITION AND CORE SOCIAL
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Ageing (CHeBA), University of New South Wales (UNSW) Sydney, Sydney,
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Background: The friends and family with whom we frequently
interact comprise our core social networks (Stiller and Dunbar,
2007). Meta-analyses indicate that poor social engagement,
including having a limited social network, is a risk factor for de-
mentia (Penninkilampi et al., 2018). Evidence for a causal relation-
ship between social network size and cognition is mixed, indicating
that larger networks protect against cognitive decline (S€orman et
al., 2017) or alternatively that network size and cognitive decline
are not associated (Kuiper et al., 2019). This research investigated
possible reciprocal associations between global cognition and core
social network size, controlling for socio-demographic and health-
related variables. Methods: Data were collected at baseline and at
2-year intervals across six years in the SydneyMemory and Ageing
Study. Structural Equation Modeling (SEM) cross-lagged panel
model (CLPM) was used to analyse longitudinal association be-
tween cognition and network size. Global cognition scores for
each wave were calculated as the average of cognitive domain
scores for the corresponding wave. Social network size was number
of friends and relatives contacted monthly. Covariates were age,
sex, education, and Geriatric Depression Scale (GDS) score
(Sheikh and Yesavage, 1986). The model included baseline covari-
ates at wave 1 and GDS score as a time-varying covariate. Results:
Respondents were 1037 Sydney residents aged 70-90 years, 55.2%
were female. Cognition and network size declined linearly across
time-points. CLPM fit indices were adequate [CFI¼0.94,
SRMR¼0.046, RMSEA¼0.08 (0.07, 0.09), Chi-Square¼279,
df¼54, p<0.0001]. Age, sex, and education significantly predicted
baseline cognition. Significant negative association between GDS
score and network size were observed at waves 1 and 4. Wave 2cognition was positively related to wave 3 network size. Post-hoc
group-based trajectory modeling indicated heterogeneous patterns
of network size trajectories across time. Conclusions: Global cogni-
tive function and core social network size declined over time.
Although lower wave 2 cognition appeared to drive reduced wave
3 network size, results generally did not support causation for either
cognition or network size for our sample. Relationship quality mat-
ters as well as quantity. Some social contact may be unsupportive.
Detection of causal associations may require longer study time-
frames and more depth in social contact data.P4-657 POPULATION PHARMACOKINETIC/PHARMACODYNAMIC ANALYSES OF
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Background: BAN2401, a humanized IgG1 monoclonal antibody
that selectively binds to Ab protofibrils, recently demonstrated
dose-dependent reduction in brain amyloid, that was accompanied
by slower decline on clinical outcomes in patients with early Alz-
heimer’s disease (AD) after 18 months of treatment, with differ-
ences observed as early as 6 months. The objective of this
analysis was to explore the relationship between 1.) pharmacoki-
netic model-predicted exposure to BAN2401 and PET standard up-
take value ratio (SUVr) assessments and 2.) SUVr assessments and
clinical endpoints (ADCOMS, CDR-SB, ADAS-Cog) at 12 and 18
months. Methods: Population pharmacokinetic model for
BAN2401 was developed using pooled data from 2 phase 1 studies
and one phase 2 study . Cerebral amyloid plaque removal was
measured in phase 2 study using PET imaging. pharmacokinetic
model-predicted BAN2401 exposures were correlated with abso-
lute SUVr measurements using indirect response Emax model.
The relationship between key clinical endpoints (ADCOMS,
CDR-SB, and ADAS-Cog) and SUVr values calculated from 2
reference regions: a) subcortical white matter (SUVrSWM) and
b) whole cerebellum mask (SUVrWC) was explored using a linear
model. Various demographic and clinical covariates were evalu-
ated. Results: Model-predicted BAN2401 concentration at the
time of SUVr assessment was correlated with a reduction in
SUVrWC and SUVrSWM. Significant covariates on Emax param-
eter were Baseline SUVrWC value and age. Emax was not signif-
icantly affected by neutralizing ADA or APOE4 carrier status for
both SUVrWC and SUVrSWM. . Reduction of amyloid as
measured by SUVrWC and SUVrSWM was positively correlated
with slowing of disease progression rate as measured by ADCOMS,
CDR-B and ADAS-Cog, except for ADAS-Cog vs SUVrWC.
Duration of treatment (18 vs 12 months) was a significant covariate
